Waldenström macroglobulinemia is a lymphoplasmocytic lymphoma involving bone marrow and characterized by the production of a monoclonal IgM gammapathy. Despite conventional chemotherapies it is an incurable disease. The recent discovery of the pro-inflammatory transcription factor MYD88 L265P mutation as a molecular signature of the disease could represent a new therapeutic target. We report here, a case of Waldenström macroglobulinemia associated with a high biological inflammatory syndrome, resistant to conventional therapies and improved by tocilizumab, an anti-interleukin-6 Receptor inhibitor.
Citation: Contis A, Mercié P, Duffau P (2015) Waldenstrom Macroglobulinemia an Auto-inflammatory Syndrome? Efficacy of Tocilizumab: A Case Report . J Mol Biomark Diagn 6:225. doi: 10.4172/2155-9929.1000225